Evidence map›Paper›PMID 33402450›Full record

ReviewIn vivo (Athens, Greece)

PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance.

Errika Voutyritsa, Christos Damaskos, Paraskevi Farmaki, Georgios Kyriakos, Evangelos Diamantis, Lourdes Victoria Quiles-SÁnchez, Anna Garmpi, Nikolaos Garmpis, Alexandros Patsouras, Athanasia Stelianidi and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. The Multifaceted Biology of PCSK9.Endocrine reviews · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Errika VoutyritsaNS Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Christos DamaskosSecond Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Paraskevi FarmakiFirst Department of Pediatrics, Agia Sofia Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Georgios KyriakosSección de Endocrinología y Nutrición, Hospital General Universitario Santa Lucia, Cartagena, Spain; giorgos6@yahoo.com.
Evangelos DiamantisDepartment of Endocrinology and Diabetes Center, G. Gennimatas General Hospital, Athens, Greece.
Lourdes Victoria Quiles-SÁnchezCentro de Salud Beniel, Murcia, Spain.
Anna GarmpiInternal Medicine Department, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos GarmpisSecond Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Alexandros PatsourasSecond Department of Internal Medicine, Tzaneio General Hospital of Piraeus, Piraeus, Greece.
Athanasia StelianidiFirst Department of Pediatrics, Agia Sofia Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Spyridon SavvanisDepartment of Internal Medicine, Elpis General Hospital of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatin intolerance refers to the inability of a patient to tolerate statin therapy, presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous patients are not treated with suitable statin-based therapy or take only very low doses. As a result, the desired decrease in low-density lipoprotein cholesterol (LDL-C) is not achieved, resulting in patients at a high risk for cardiovascular events, requiring an alternative lipid-lowering treatment. Common treatments manage to reduce the LDL-C level by up to 20%. Recently, new alternative treatment options have been proved to lower the LDL-C level by up to 70%. These treatment strategies are based on human monoclonal antibodies against protein convertase subtilisin/kexin 9 (PCSK9). MATERIALS AND

methodsHerein, we review the efficiency of anti-PCSK9 in treatment of hypercholesterolemic patients with statin intolerance. We focused on the use of PCSK9 inhibitors in statin-intolerant patients and we estimated the clinical results concerning the reduction of the mean LDL-C concentration and the side effects that were observed.

resultsIn the majority of cases, treatment strategy based on PCSK9 was successful and achieved the end-points.

conclusionPCSK9 inhibition can be considered as a treatment of option for lipid-lowering in statin-intolerant patients.

Indexed as

Anticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsAntibodies, Monoclonal, HumanizedHumansProprotein Convertase 9SubtilisinAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 protein, humanProprotein Convertase 9SubtilisinalirocumabAnti-PCSK9evolocumabhypercholesterolemiastatin intolerance

Identifiers

PMID33402450
PMCPMC7880798

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.